Cliff brings over 25 years of life science industry experience to Scancell in the development and commercialisation of emerging technologies and therapeutic products including licensing, M&A, corporate financing and operations management. Most recently he was Chief Business and Operating Officer of Benitec Biopharma Ltd (ASX:BLT, NASDAQ:BNTC). Prior to his role at Benitec he held the position of Managing Director at Sienna Cancer Diagnostics Ltd (ASX:SDX), and also for therapeutic antibody development companies Immune System Therapeutics Ltd and Biosceptre International Ltd. He was formerly VP of Business Development at Arana Therapeutics Ltd, which was acquired by US-based Cephalon Inc (now Teva) in 2009, and he is currently a director of investment fund Newstar Ventures Pty Ltd. Cliff holds a Bachelor of Pharmacy and a PhD in Medicinal Chemistry from the University of Nottingham.
Lindy is an internationally recognised immunologist in the field of tumour therapy, She has worked for over 20 years in translational research, developing products for clinical trials including monoclonal antibodies for diagnostic imaging and therapy and cancer vaccines. She has a personal Chair in Cancer Immunotherapy at the Department of Clinical Oncology at the University of Nottingham.
Dr Sally Adams was Head of Neurology & Virology at British Biotech and Development Director at Neures Limited before becoming an independent consultant providing drug development and management services within the biotechnology and pharmaceutical sectors, specialising in biological entities. She has worked on many complex projects over the past 25 years including anti-infective vaccines, cancer immunotherapies and an innovative stem cell treatment for visual dysfunction. Sally previously worked as a development consultant to Scancell, providing guidance on the development of SCIB1, before her appointment as Development Director in May 2014.
Keith trained and qualified as a chartered accountant with Peat Marwick (now KPMG). He spent twenty years in the accounting profession before joining a private medical diagnostic company as Financial Director. Since 2003 he has taken on many consultancy and interim finance roles for private and AIM listed companies in the life sciences sector. Keith started working for Scancell on a part-time basis in January 2010 and took up this full-time role in September 2016.
Here we take a closer look at Scancell, which is at the vanguard of immuno-oncology
Mon, 20 May 2019 09:51:00
Scancell has a clinical development partnership with Cancer Research UK, the world's leading cancer charity dedicated to saving lives through research
Mon, 20 May 2019 06:23:00
“The initial focus of the board will be to inform the clinical strategy for the planned Modi-1 clinical trial and to ensure the best possible outcome in several solid tumour indications”
Fri, 10 May 2019 05:45:00